Biosimilars
-
Affordable Care Act, Biosimilars, Drug Prices, DTC, Generics, Healthcare Costs, Medicaid, Utilization Management, VaccinesAMP is WAC — 03/20/26
Read more: AMP is WAC — 03/20/26What.a.week. The whirlwind of the Access conference, tons of pharmaceutical health policy news – and apparently a whole lot of new subscribers. Hi, welcome. Quick intro: I’m Jennifer Snow, I run Apteka Policy, 25 years in pharmaceutical health policy. I take the dense policy stuff – IRA negotiations, 340B fights, PBM reform – and tell…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Affordable Care Act, Biosimilars, Caught my eye, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Utilization ManagementAMP is WAC — 2/13/26
Read more: AMP is WAC — 2/13/26I chuckled during the E&C hearing when members were questioning the panelists about the pharmaceutical deals with the Administration. As if these are the people they should be asking. Make a left, make right, go down about a mile – there’s a big white house. Maybe they can help you there. Parallels Between 340B and…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Medicare Advantage, Pharmacy Benefit Managers, Reference PricingAMP is WAC — 1/22/26
Read more: AMP is WAC — 1/22/26I swear that inside I’m an 8-year-old at times (one that likes to make cocktails, but still), I am so excited about a snowstorm. Real snowfall! Cozy inside time interspersed with time shoveling out alongside neighbors. Watching the kids sled in front of the elementary school. Pulling out the snowshoes and remembering that they aren’t…
-
Affordable Care Act, Alzheimer’s, Biosimilars, Caught my eye, Drug shortages, FDA, Medicaid, Medicare Part D, UncategorizedAMP is WAC — 11/14/25
Read more: AMP is WAC — 11/14/25How is it mid-November? I think of all of the things that need to get done by the end of the year and then try and pull out the productivity schemes (5 choices, pomodoro, eat the frog, etc.) I’ve learned over the years. The problem is that none of these create more time, just make…
-
Biosimilars, Caught my eye, Generics, Health Equity, ICER, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit Managers, State-based Reform, Utilization Management, ValueAMP is WAC — 10/31/25
Read more: AMP is WAC — 10/31/25You won’t be surprised when I tell you that my favorite Halloween costume was when I wore a pair of scrubs with vinyl records attached (Spin Doctor). Yep. Right up there with Freudian slips. This year I will stick to my usual costume: the nice lady who hands out full-size bars to 200+ neighborhood kids.…
-
AMP is WAC — 7/18/25
Read more: AMP is WAC — 7/18/25I have a case of existential dread, and yet the world keeps spinning so let’s do this… Caught my Eye More Cowbell. Late last year I put out a report on biosimilars and it called out how the Inflation Reduction Act could hurt innovation and savings for biosimilars. Here is a report from Matrix Global…
-
Affordable Care Act, Biosimilars, Caught my eye, Employers, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, Utilization ManagementAMP is WAC — 6/27/25
Read more: AMP is WAC — 6/27/25In case you think I’m opinionated, just know that it could be so.much.worse. I often write something and then hit backspace, backspace, backspace. You’re welcome? Off next week for the 4th of July. Caught my Eye Tradeoffs. Last week USC put out a paper that reviewed how many Medicare Part D beneficiaries will likely pay…
-
AMP is WAC — 6/13/25
Read more: AMP is WAC — 6/13/25Caught my Eye Make Believe. This week we were wondering if the Administration would put out information on what the Most Favored Nation (MFN) would be for drugs; that is what is the best price for each drug in a set of country’s that have a GDP at least 60% of ours. But there have…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)